Management of marker negative stage II testicular cancer

Durvalumab plus tremelimumab or durvalumab monotherapy in metastatic urothelial carcinoma

Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma

Genetic mutations: New therapeutic avenues in metastatic prostate cancer

6-factor prognostic model for patients with advanced urothelial carcinoma

Comment: Urothelial cancer research from ASCO GU 2018

VinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis

Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy

Tumour fraction in circulating free DNA as a biomarker of disease dynamics in metastatic prostate cancer

Crizotinib for advanced papillary renal cell carcinoma with MET mutations or amplification

Serum miRNA to predict post-chemotherapy viable disease in testicular non-seminomatous germ cell tumour patients

Radium-223 for bone predominant metastatic castration resistant prostate cancer

FALCON: Impact of 18F-fluciclovine PET/CT on management of biochemically recurrent prostate cancer

PROSPER RCC study of perioperative nivolumab for renal cell carcinoma - future trial

POUT: Phase III randomised trial of perioperative chemotherapy vs surveillance in upper tract urothelial cancer

Latest in adjuvant therapy for renal cell carcinoma

Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer